Aurobindo Pharma's Eugia unit has been designated as a 'Official Action Indicated' (OAI) facility by the U.S. FDA following an inspection, indicating potential issues that may require corrective actions to meet regulatory standards.

Aurobindo Pharma experienced a drop in its quality rating to 'Average' by MarketsMojo on May 25, 2026. The downgrade is due to concerns over the company's financial health, including lower returns on equity (ROE), returns on capital employed (ROCE), elevated debt levels, and inconsistent growth.

Aurobindo Pharma's US subsidiary successfully passed an FDA inspection, receiving an Observationally Approved status with four minor observations. This event is expected to have no significant financial implications for the company.

Analysts anticipate potential gains of up to 25% in Sun Pharma, Zydus Lifesciences, and Aurobindo Pharma. Investors may consider these stocks after evaluating the suggested 'BUY' recommendations and target prices for informed decision-making.

Elara Capital maintains a positive outlook towards Aurobindo Pharma, raising their price target to an optimistic ₹1,805, indicating a strong potential for growth and recommending investors to consider buying shares in the company.

CLSA has adjusted its stance on Aurobindo Pharma to 'Hold', yet boosted the price target to ₹1,490. This change is due to robust European sales growth counterbalancing weak US sales, with promising prospects anticipated following FY28.

Bank of America Maintains a 'Buy' rating for Aurobindo Pharma, with a price target set at ₹1700. This is based on the company's expected stable EBITDA and margin expansion. The analysts also highlight potential growth in US revenue due to the Lannett deal and a 21% margin forecast as key positives.

Aurobindo Pharma's subsidiary Agile Pharma BV has established a new company, Arrow Pharma Production SAS in France. This new entity will specialize in the production of generic pharmaceuticals and is entirely owned by Aurobindo with an initial investment of €100K.

Aurobindo Pharma reports a 13% drop in Q4 sales for the U.S., with earnings before interest, taxes, depreciation, and amortization (EBITDA) decreasing by 5% year-over-year.

Despite reporting Q4 growth, Aurobindo Pharma's shares experienced a downturn, suggesting potential investor unease or broader market factors influencing the decline.

Today, Aurobindo Pharma, Nykaa, Hindalco, GAIL, and LIC are attracting attention due to the upcoming Q4 results and associated news updates, potentially influencing market action.

Aurobindo Pharma reported an EBITDA of ₹1,801 crore for Q4, despite foreign exchange losses, maintaining a strong margin of 20.3%.

Aurobindo Pharma aims to achieve an EBITDA margin of over 21% by FY27 and anticipates a significant growth in formulation revenue, projected to reach $2B in the coming years.

Aurobindo Pharma has established a new subsidiary, Arrow Pharma Production SAS, in France, which is dedicated to increasing the production of generic pharmaceuticals with an initial investment of 100,000 EUR.

Aurobindo Pharma reported a 5.6% increase in Q4 revenue to INR 8,853 Crore, with the European segment experiencing a significant boost of 30.2%. However, US revenue dropped by 13%, while the ARV business saw growth of 6.4%. The company posted a net profit of INR 921 Crore and maintained strong cash flow.

Bernstein has recommended investing in Zydus, Lupin, and Sun Pharma, predicting a potential $75 billion growth in India's biopharmaceutical sector over the next decade. The firm believes that innovation, AI integration, and focus on niche therapies could propel this growth, with Zydus being their top choice. Biocon and Mankind Pharma were rated as less promising investments.

Aurobindo Pharma recently discussed their Q4 FY2026 financial results in an earnings call, offering insights into factors impacting their stock price. The call's transcript is worth examining for those interested in understanding the company's performance in the most recent quarter.

Aurobindo Pharma's shares dropped by 5.8% on Friday due to Q4 results, despite a 2% increase in profit and a 5.6% revenue growth. The decline was primarily attributed to a 13% drop in US business earnings, while the EU business showed a significant 30.2% growth. However, EBITDA margins narrowed to 19.2%.

Aurobindo Pharma reported a decrease in Q4 EBITDA to ₹17.6 billion, marking a year-over-year drop compared to ₹19 billion. The company also experienced a narrowed EBITDA margin at 20.2%, down from 22.98% last year.

Anticipation builds for Aurobindo Pharma's Q4 results, with analysts sharing their views on the earnings via #AwaazEarnings. Stay tuned for updates on the company's performance.

Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.

Aurobindo Pharma's options interest climbed by 19.8%, suggesting a positive trend in the pharmaceutical industry, with over 55,000 contracts traded. This surge in volume and price action could be a sign of growing optimism among investors in this sector.

Aurobindo Pharma reaches a new 52-week high of ₹1529.9, marking significant growth of 26.3% year-over-year. This milestone is attributed to strong technical momentum, while the Sensex maintains a cautious trading approach.

Aurobindo Pharma's CuraTeQ has received approval from CDSCO for Bevqolva, a biosimilar to bevacizumab. This authorization allows for the production and marketing of Bevqolva in Hyderabad, increasing Aurobindo's oncology portfolio.

Analyst Ajit Mishra advises investors to consider short-term investments in Aurobindo Pharma, Sona BLW, and Tata Steel due to their promising potential returns. The Nifty index displays a mixed recovery influenced by global trends, with long positions favored in the pharma, metals, and energy sectors.

Aurobindo Pharma recently executed a significant block trade on the NSE for approximately INR 45.4 crore, involving around 303,451 shares at an indicative price of INR 1,495.1 each.

Aurobindo Pharma will disclose their Q4 and full-year FY2026 results during a board meeting set for May 21, 2026. The trading window for the company remains closed until May 23, resuming on May 24, 2026.

Aurobindo shares rise due to the U.S. FDA's grant of VAI status, increasing investor optimism. Wockhardt posts profits for Q4, signaling a positive shift in their financial standing.

Aurobindo Pharma's Unit VII received a Form 483 with nine observations from the US FDA following an inspection between January 28 and February 10, 2026. The findings indicate potential issues that require voluntary action to address.

The US Food and Drug Administration (FDA) has classified Aurobindo Pharma's manufacturing facility in Telangana as a Voluntary Action Indicated, following a series of nine inspection findings (Form 483). This suggests that the company needs to address certain issues voluntarily to meet FDA standards.

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has secured approval from Health Canada for Bevqolva™, a cancer drug similar to bevacizumab. This drug works by hindering angiogenesis and is currently under evaluation by the CHMP in Europe, with an existing launch in the UK market.

Aurobindo Pharma experiences a significant increase of 20.6% in options interest (OI), suggesting growing bullish sentiments, as the stock price approaches its 52-week high, indicating robust trading activity.

CLSA anticipates potential Nifty gains due to a fresh breadth thrust signal. The index has already gained 2000 points from its April lows. Notable midcap stocks recommended for investment by Laurence Balanco include BSE, MCX, Apollo Tubes, Dixon Tech, and Aurobindo Pharma.

Aurobindo Pharma recently executed a significant block trade on the NSE, selling 241,320 shares at around Rs. 1371.9 per share, totaling an impressive Rs. 33.1 crores.

UltraTech Cement set to overtake other global players, reaching a capacity of 200 MTPA, making it the largest outside China by adding 8.7 MTPA through three new units. On the other hand, pharmaceutical companies Lupin, Aurobindo, and Cipla face potential disruptions as they undergo USFDA inspections, while HG Infra, EMS, and Zee focus on infrastructure and media sectors.

Aurobindo Pharma has received approval from the US Food and Drug Administration (FDA) for a new drug, Dextromethorphan Polistirex Oral Suspension, with an estimated market value of $138 million by February 2026. The company plans to launch this product in the second quarter of their fiscal year 2027.

Kush Bohra suggests investing in Aurobindo Pharma, Nava, and Pokarna for quick profits due to their robust technical indicators. He sets targets at Rs 1415/1480 for Aurobindo, Rs 628/645 for Nava, and Rs 945/965 for Pokarna. It's important to monitor these investments closely with stop-loss levels in place.

Aurobindo Pharma secures USFDA approval for the $50.2 million Glycerol Phenylbutyrate Oral Liquid, expanding their US FDA-approved generic drugs to 579. This move strengthens their presence in the American pharmaceutical market.

Aurobindo Pharma's Rs 800 crore share buyback at Rs 1,475 per share concludes today. If you want to participate, make sure to purchase shares before the ex-date on April 16.

Aurobindo Pharma's subsidiary has entered into a product agreement with MSD Singapore, marking a significant step forward. The company also announced plans to invest between $150-$175 million in building a new drug substance facility equipped with a 60,000L bioreactor.